drugset / Trial / NCT00728780

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

NCT00728780

Phase 1 Completed 32 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.

Timeline

Start
2008-08
Primary completion
2008-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABT-335 Small molecule 135 mg
Comparator Rosuvastatin Small molecule 15 mg

Indications

No indication recorded.